Should I buy or sell Ginkgo Bioworks stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares. View DNA analyst ratings or view top-rated stocks .

What is Ginkgo Bioworks' stock price target for 2024?

5 Wall Street research analysts have issued 1 year target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.10 to $3.00. On average, they predict the company's stock price to reach $2.20 in the next twelve months. This suggests a possible upside of 154.4% from the stock's current price. View analysts price targets for DNA or view top-rated stocks among Wall Street analysts .

How have DNA shares performed in 2024?

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has decreased by 48.8% and is now trading at $0.8649. View the best growth stocks for 2024 here .

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our DNA earnings forecast .

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $34.76 million for the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 48.23% and a negative net margin of 355.08%. The company's quarterly revenue was down 64.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.04) earnings per share.

What ETFs hold Ginkgo Bioworks' stock?

ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , ARK Genomic Revolution ETF (ARKG) , Direxion Moonshot Innovators ETF (MOON) , ARK Innovation ETF (ARKK) , ROBO Global Artificial Intelligence ETF (THNQ) , IQ U.S. Mid Cap R&D Leaders ETF (MRND) , Range Cancer Therapeutics ETF (CNCR) and Putnam BioRevolution ETF (SYNB) .

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $215.0 million-$235.0 million, compared to the consensus revenue estimate of $279.6 million.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.60%), Salem Investment Counselors Inc. (0.22%), Green Alpha Advisors LLC (0.01%) and Quattro Financial Advisors LLC (0.01%). Insiders that own company stock include Barry Canton , Christian O Henry , Jason R Kelly , Marie E Fallon, Marijn E Dekkers , Mark E Dmytruk , Reshma P Shetty and Shyam Sankar. View institutional ownership trends .

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free DNA Stock Alerts

$0.86

-0.06 (-6.46%)

(As of 04:10 PM ET)

Compare

Today's Range: $0.85
▼
$0.94
50-Day Range: $0.87
▼
$1.55
52-Week Range: $0.85
▼
$2.55

Volume: 38.80 million shs
Average Volume: 23.52 million shs
Market Capitalization: $1.86 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.20

Get Ginkgo Bioworks alerts:

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 154.4% Upside
$2.20 Price Target
Short Interest: Bearish
20.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 6 Articles This Week
Insider Trading: Selling Shares
$101,606 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.32) to ($0.28) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

751st out of 918 stocks

Biological Products, Except Diagnostic Industry

128th out of 151 stocks

3.0

Analyst's Opinion

Consensus Rating
Ginkgo Bioworks has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Ginkgo Bioworks has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
20.21% of the float of Ginkgo Bioworks has been sold short.
Short Interest Ratio / Days to Cover
Ginkgo Bioworks has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Ginkgo Bioworks has recently increased by 3.28%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ginkgo Bioworks does not currently pay a dividend.
Dividend Growth
Ginkgo Bioworks does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DNA.

2.3

News and Social Media Coverage

News Sentiment
Ginkgo Bioworks has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Ginkgo Bioworks this week, compared to 5 articles on an average week.
Search Interest
Only 48 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
46 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 18% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $101,606.00 in company stock.
Percentage Held by Insiders
15.05% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.32) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ginkgo Bioworks is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ginkgo Bioworks is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ginkgo Bioworks has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications.

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets.

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award.

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022.

DNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DNA Stock News Headlines

April 5, 2024 | insidertrades.com

Mark E. Dmytruk Sells 51,169 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock

April 16, 2024 | uk.finance.yahoo.com

1 growth stock to consider buying at $1 that could be the next Nvidia

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 16, 2024 | bizjournals.com

Ginkgo to fold AgBiome microbial strain library into its West Sacramento AgBio center

April 16, 2024 | prnewswire.com

Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products

April 12, 2024 | businesswire.com

Modalis Announces Partnership with Ginkgo Bioworks

April 11, 2024 | uk.investing.com

Ginkgo Bioworks and Novo Nordisk enhance R&D partnershi

April 11, 2024 | markets.businessinsider.com

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 11, 2024 | msn.com

Ginkgo Bioworks acquires AgBiome's platform assets

April 11, 2024 | prnewswire.com

Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"

April 11, 2024 | prnewswire.com

Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets

April 10, 2024 | stockhouse.com

Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks

April 10, 2024 | markets.businessinsider.com

Ginkgo Bioworks Announces Expansion Of Partnership With Novo Nordisk - Quick Facts

April 10, 2024 | prnewswire.com

Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain

April 10, 2024 | prnewswire.com

Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks

April 9, 2024 | fool.com

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

April 8, 2024 | prnewswire.com

IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

April 4, 2024 | uk.investing.com

Ginkgo Bioworks acquires Modulus Therapeutics assets

April 4, 2024 | finance.yahoo.com

Ginkgo Bioworks to Host 5th Annual Ferment Conference

April 3, 2024 | prnewswire.com

Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing

April 3, 2024 | fool.com

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

April 2, 2024 | finance.yahoo.com

Ginkgo, in search of more cell therapy tools, buys another startup

April 2, 2024 | markets.businessinsider.com

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Platform Assets

April 2, 2024 | prnewswire.com

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

March 28, 2024 | msn.com

Ginkgo wins DARPA contract to develop de-icing products

March 28, 2024 | prnewswire.com

Ginkgo Bioworks Awarded DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments

See More Headlines

Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:DNA
CUSIP: N/A
CIK: 1830214
Web: www.eagleequityptnrs.com
Phone: 877-442-5362
Fax: N/A
Employees: 1,218
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.20
High Stock Price Target: $3.00
Low Stock Price Target: $1.10
Potential Upside/Downside: +137.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-892,870,000.00
Net Margins: -355.08%
Pretax Margin: -355.11%
Return on Equity: -48.23%
Return on Assets: -31.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.11
Quick Ratio: 6.11

Sales & Book Value

Annual Sales: $251.46 million
Price / Sales: 7.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.55 per share
Price / Book: 1.68

Miscellaneous

Outstanding Shares: 2,152,400,000
Free Float: 1,828,460,000
Market Cap: $1.99 billion
Optionable: Optionable
Beta: 1.35

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Jason Kelly (Age 42)
Founder, CEO & Director
Comp: $262.5k
Dr. Reshma P. Shetty (Age 42)
Founder, President, COO & Director
Comp: $262.5k
Mr. Mark E. Dmytruk (Age 52)
Chief Financial Officer
Comp: $465.25k
Mr. Thomas Knight Jr.
Founder
Mr. Austin Che
Founder, Head of Strategy & Treasurer
Mr. Bartholomew Canton
Founder, CTO & Secretary
Mr. Steven P. Coen CPA
Chief Accounting Officer
Karen Tepichin
General Counsel & Secretary
Ms. Anna Marie Wagner
Senior Vice President of Corporate Development
Ms. Samantha Sutton
Head of People

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.
What is Ginkgo Bioworks' stock price target for 2024?: 5 Wall Street research analysts have issued 1 year target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.10 to $3.00. On average, they predict the company's stock price to reach $2.20 in the next twelve months. This suggests a possible upside of 154.4% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.
How have DNA shares performed in 2024?: Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has decreased by 48.8% and is now trading at $0.8649.
View the best growth stocks for 2024 here.
When is Ginkgo Bioworks' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our DNA earnings forecast.
How were Ginkgo Bioworks' earnings last quarter?: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $34.76 million for the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 48.23% and a negative net margin of 355.08%. The company's quarterly revenue was down 64.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.04) earnings per share.

What ETFs hold Ginkgo Bioworks' stock?: ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), ARK Innovation ETF (ARKK), ROBO Global Artificial Intelligence ETF (THNQ), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Range Cancer Therapeutics ETF (CNCR) and Putnam BioRevolution ETF (SYNB).
What guidance has Ginkgo Bioworks issued on next quarter's earnings?: Ginkgo Bioworks updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $215.0 million-$235.0 million, compared to the consensus revenue estimate of $279.6 million.
Who are Ginkgo Bioworks' major shareholders?: Ginkgo Bioworks' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.60%), Salem Investment Counselors Inc. (0.22%), Green Alpha Advisors LLC (0.01%) and Quattro Financial Advisors LLC (0.01%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.
How do I buy shares of Ginkgo Bioworks?: Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial